Authors:
Address: U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
Journal:

Publication:

abstract

Developing vaccines for highly pathogenic viruses such as those causing Lassa, Ebola, and Marburg hemorrhagic fevers is a daunting task due to both scientific and logistical constraints. Scientific hurdles to overcome include poorly defined relationships between pathogenicity and protective immune responses, genetic diversity of viruses, and safety in a target population that includes a large number of individuals with compromised immune systems. Logistical obstacles include the requirement for biosafety level-4 containment to study the authentic viruses, the poor public health infrastructure of the endemic disease areas, and the cost of developing these vaccines for use in non-lucrative markets. recombinant DNA-based vaccine approaches offer promise of overcoming some of these issues. In this review, we consider the status of various recombinant DNA candidate vaccines against Lassa virus and filoviruses which have been tested in animals.

Published by Elsevier B.V.

Related Articles
Review Progress in filovirus vaccine development: evaluating the potential for clinical use.
Expert Rev Vaccines. 2011
Review Progress in filovirus vaccine development: evaluating the potential for clinical use.
Falzarano D, Geisbert TW, Feldmann H. Expert Rev Vaccines. 2011 Jan; 10(1):63-77.
Review Prospects for immunisation against Marburg and Ebola viruses.
Rev Med Virol. 2010
Review Prospects for immunisation against Marburg and Ebola viruses.
Geisbert TW, Bausch DG, Feldmann H. Rev Med Virol. 2010 Nov; 20(6):344-57.
Review Vaccine research efforts for filoviruses.
Int J Parasitol. 2003
Review Vaccine research efforts for filoviruses.
Hart MK. Int J Parasitol. 2003 May; 33(5-6):583-95.
Review Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.
J Infect Dis. 2011
Review Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.
Geisbert TW, Feldmann H. J Infect Dis. 2011 Nov; 204 Suppl 3:S1075-81.
Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections.
Clin Vaccine Immunol. 2008
Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections.
Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, Holman DH, Dong JY, Pratt WD. Clin Vaccine Immunol. 2008 Mar; 15(3):460-7. Epub 2008 Jan 23.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster